Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 45 Breast Neoplasms 39 Triple Negative Breast Neoplasms 19 Prostatic Neoplasms 17 Neoplasms 13 Fallopian Tube Neoplasms 13 Endometrial Neoplasms 12 Recurrence 8 Pancreatic Neoplasms 8 Neoplasm Metastasis 8 Squamous Cell Carcinoma of Head and Neck 7 Small Cell Lung Carcinoma 7 Lung Neoplasms 6 Carcinoma, Ovarian Epithelial 6 Glioma 5 Glioblastoma 5 Carcinoma, Renal Cell 5 Uterine Cervical Neoplasms 4 Sarcoma 4 Carcinoma, Squamous Cell 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Breast Cancer 4 Stomach Neoplasms 3 Solid Tumor 3 Melanoma 3 Head and Neck Neoplasms 3 Fanconi Anemia, Complementation Group D1 3 Uveal Melanoma 2 Uterine Neoplasms 2 Urinary Bladder Neoplasms 2

Interventions

Cisplatin 104 Radiotherapy, Intensity-Modulated 59 Gemcitabine 53 toripalimab 35 Fluorouracil 30 Docetaxel 30 Capecitabine 28 Radiotherapy 23 Drug Therapy 20 camrelizumab 19 nimotuzumab 16 nedaplatin 12 Chemoradiotherapy 12 sintilimab 11 apatinib 11 Induction Chemotherapy 11 Immune Checkpoint Inhibitors 11 spartalizumab 10 endostar protein 8 Paclitaxel 8 Cetuximab 8 tislelizumab 7 pembrolizumab 7 Endostatins 7 Bevacizumab 7 anlotinib 6 Radiation 6 Endoscopy 6 fludarabine 5 S 1 (combination) 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Nasopharyngeal Carcinoma × olaparib × Clear all

NCT04825990 2026-06-01

POINT

Gruppo Oncologico del Nord-Ovest

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡